These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7570657)

  • 1. Summary of panel discussion on the 'advantages/limitations/uncertainties in the use of physiologically based pharmacokinetic and pharmacodynamic models in hazard identification and risk assessment of toxic substances'.
    Frederick CB
    Toxicol Lett; 1995 Sep; 79(1-3):201-6. PubMed ID: 7570657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances.
    Leung HW; Paustenbach DJ
    Toxicol Lett; 1995 Sep; 79(1-3):55-65. PubMed ID: 7570674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances.
    Clewell HJ
    Toxicol Lett; 1995 Sep; 79(1-3):207-17. PubMed ID: 7570658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA; Tessari JD
    Toxicol Lett; 1995 Sep; 79(1-3):193-200. PubMed ID: 7570656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances.
    Medinsky MA
    Toxicol Lett; 1995 Sep; 79(1-3):185-91. PubMed ID: 7570655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of mechanistic information in risk assessment for toxic chemicals.
    Becking GC
    Toxicol Lett; 1995 May; 77(1-3):15-24. PubMed ID: 7618129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case study illustrating the WHO IPCS guidance on characterization and application of physiologically based pharmacokinetic models in risk assessment.
    Meek ME; Barton HA; Bessems JG; Lipscomb JC; Krishnan K
    Regul Toxicol Pharmacol; 2013 Jun; 66(1):116-29. PubMed ID: 23535119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.
    el-Masri HA; Thomas RS; Benjamin SA; Yang RS
    Toxicology; 1995 Dec; 105(2-3):275-82. PubMed ID: 8571364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapolating the future: research trends in modeling.
    Menzel DB
    Toxicol Lett; 1995 Sep; 79(1-3):299-303. PubMed ID: 7570670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of physiologically based pharmacokinetic models for use in risk assessment.
    Chiu WA; Barton HA; DeWoskin RS; Schlosser P; Thompson CM; Sonawane B; Lipscomb JC; Krishnan K
    J Appl Toxicol; 2007; 27(3):218-37. PubMed ID: 17299829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologically motivated quantitative models and the mixture toxicity problem.
    Conolly RB
    Toxicol Sci; 2001 Sep; 63(1):1-2. PubMed ID: 11509736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of acute chemical incidents as a first step in evaluating the usefulness of physiologically based pharmacokinetic models in such incidents.
    Hunault CC; Boerleider RZ; Hof BG; Kliest JJ; Meijer M; Nijhuis NJ; de Vries I; Meulenbelt J
    Clin Toxicol (Phila); 2014 Feb; 52(2):121-8. PubMed ID: 24446967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in the pharmacokinetics of trichloroethylene and its metabolites.
    Chiu WA; Okino MS; Lipscomb JC; Evans MV
    Environ Health Perspect; 2006 Sep; 114(9):1450-6. PubMed ID: 16966104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
    Marino DJ; Starr TB
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose.
    Simmons JE; Evans MV; Boyes WK
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):927-50. PubMed ID: 16020185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on collaboration and infrastructure development: industry perspectives.
    Knaak JB
    Toxicol Lett; 1995 Sep; 79(1-3):305-12. PubMed ID: 7570671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational pharmacokinetics during developmental windows of susceptibility.
    Barton HA
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):889-900. PubMed ID: 16020183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry.
    el-Masri HA; Mumtaz MM; Choudhary G; Cibulas W; De Rosa CT
    Int J Hyg Environ Health; 2002 Mar; 205(1-2):63-9. PubMed ID: 12018017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.